Ben Enejo
Partner
Ben assists top healthcare clients across Regulatory & Medical Affairs functions, as well as Commercial Strategy & Operations, with a specialty in business transformation and operational excellence initiatives.
Areas of Focus
Education
Cranfield School of Management
Master of Business Administration
Cranfield University
M.Sc. Molecular Medicine
Nottingham Trent University
B.Sc. Physiology & Pharmacology
Past Experience
PA Consulting Group
Healthcare Management Consultant
Astra Zeneca
Patient Safety Advisor
Janssen Pharmaceuticals (Johnson & Johnson)
Pharmacovigilance Associate
Medical Gases Ltd
Sales Engineer (Business Development)
Ben is a Partner at Arthur D. Little, based in our Boston office, and a member of our global Healthcare & Life Sciences Practice.
Ben is an experienced management consultant and industry expert having worked with various global biopharmaceutical companies on strategies to accelerate the development of new medicines through to commercialization. Particular areas of expertise include clinical trial acceleration, R&D transformation including advanced technology application, increasing success for rare disease drug development and launch, patient and drug safety, and quality and compliance excellence.
Ben holds an MBA with other qualifications in Molecular Medicine, Pharmacology and Physiology, and Program management.
Why patient centricity is key to long-term pharma company success
Patient centricity seems to be an obvious focus for pharmaceutical companies. After all, their core business is to develop drugs and treatments to meet specific patient needs.
Yet, patient centricity is not evident across the end-to-end pharma value chain, from identifying unmet patient needs through drug discovery and development to product availability and treatment. For example, on average, 30% of patients leave clinical trials before their scheduled treatment completion date, often because of the high burden of the trials on their lives.
The future of pharmacovigilance
While assessing the safety and efficacy of medicines is the bedrock in drug research, vaccine development during the COVID-19 pandemic highlighted the changes in the types of medicines developed today and the stakeholder management required for successful adoption. Enabled by new treatment paradigms, digital transformation, advanced technology applications, data availability, and the patient-centric focus, the changing ecosystem requires new capabilities in assessing the safety of medicines and managing the new entities at play.
CAR-T on site: Forgoing the extra mile
CAR-T (chimeric antigen receptor T-cell) therapy involves the use of genetically re-engineered versions of a patient’s own T-cells to find cancer cells and defeat them. As of March 2020, there are two CAR-T therapies licensed for use – Kymriah® and Yescarta®. CAR-T has pushed the boundaries of medicine, and the success observed in patient treatment has created interest in the use of CAR-T to treat a number of other types of tumors. This is evidenced by the number of clinical trials involving the use of CAR-T to treat a range of cancers (Figures below).
Managing clinical trials during COVID-19 and beyond
One of the many consequences of the COVID-19 crisis has been difficulty in continuing to enroll and run clinical trials, which typically involve large numbers of people interacting in multiple geographies. Arthur D. Little (ADL) has pioneered and deployed a new, risk-based predictive analytical approach, powered by machine-learning technology. It enables pharma companies to make much better predictions and forecasts to support decision-making around key issues, such as adapting patient targets to favor less affected and recovering geographies, program extensions, and new trials.
Maximizing the rare chance of launch success with orphan drugs
The BIG patent expiry question: Why sink when you can sail?
As a biopharmaceutical product approaches the end of its patent life, executives believe that the product’s demise is inevitable and will happen at great speed. They begin to worry about the rapid loss of revenue that will be brought about by the entry of generic alternatives into the market. They believe that there are only two outcomes possible for the product: die quickly or die slowly. This fatalistic outlook motivates the selection of a loss-of-exclusivity (LOE) strategy to achieve a slow demise rather than a quick one.
Pharmacovigilance literature review in the age of precision medicine
Over the years, pharmacovigilance (PV) processes have involved PV professionals manually going through high volumes of data to identify, assess and report adverse event (AE) information. This set-up will face increasing challenges, as more and more work needs to be done in fixed amounts of time. The options for addressing the challenges can either be labor intensive or technology enabled. Technology-enabled processes have the advantage of being sustainable over time, with the added benefit of potential savings in time and costs.
Ben is a Partner at Arthur D. Little, based in our Boston office, and a member of our global Healthcare & Life Sciences Practice.
Ben is an experienced management consultant and industry expert having worked with various global biopharmaceutical companies on strategies to accelerate the development of new medicines through to commercialization. Particular areas of expertise include clinical trial acceleration, R&D transformation including advanced technology application, increasing success for rare disease drug development and launch, patient and drug safety, and quality and compliance excellence.
Ben holds an MBA with other qualifications in Molecular Medicine, Pharmacology and Physiology, and Program management.
Why patient centricity is key to long-term pharma company success
Patient centricity seems to be an obvious focus for pharmaceutical companies. After all, their core business is to develop drugs and treatments to meet specific patient needs.
Yet, patient centricity is not evident across the end-to-end pharma value chain, from identifying unmet patient needs through drug discovery and development to product availability and treatment. For example, on average, 30% of patients leave clinical trials before their scheduled treatment completion date, often because of the high burden of the trials on their lives.
The future of pharmacovigilance
While assessing the safety and efficacy of medicines is the bedrock in drug research, vaccine development during the COVID-19 pandemic highlighted the changes in the types of medicines developed today and the stakeholder management required for successful adoption. Enabled by new treatment paradigms, digital transformation, advanced technology applications, data availability, and the patient-centric focus, the changing ecosystem requires new capabilities in assessing the safety of medicines and managing the new entities at play.
CAR-T on site: Forgoing the extra mile
CAR-T (chimeric antigen receptor T-cell) therapy involves the use of genetically re-engineered versions of a patient’s own T-cells to find cancer cells and defeat them. As of March 2020, there are two CAR-T therapies licensed for use – Kymriah® and Yescarta®. CAR-T has pushed the boundaries of medicine, and the success observed in patient treatment has created interest in the use of CAR-T to treat a number of other types of tumors. This is evidenced by the number of clinical trials involving the use of CAR-T to treat a range of cancers (Figures below).
Managing clinical trials during COVID-19 and beyond
One of the many consequences of the COVID-19 crisis has been difficulty in continuing to enroll and run clinical trials, which typically involve large numbers of people interacting in multiple geographies. Arthur D. Little (ADL) has pioneered and deployed a new, risk-based predictive analytical approach, powered by machine-learning technology. It enables pharma companies to make much better predictions and forecasts to support decision-making around key issues, such as adapting patient targets to favor less affected and recovering geographies, program extensions, and new trials.
Maximizing the rare chance of launch success with orphan drugs
The BIG patent expiry question: Why sink when you can sail?
As a biopharmaceutical product approaches the end of its patent life, executives believe that the product’s demise is inevitable and will happen at great speed. They begin to worry about the rapid loss of revenue that will be brought about by the entry of generic alternatives into the market. They believe that there are only two outcomes possible for the product: die quickly or die slowly. This fatalistic outlook motivates the selection of a loss-of-exclusivity (LOE) strategy to achieve a slow demise rather than a quick one.
Pharmacovigilance literature review in the age of precision medicine
Over the years, pharmacovigilance (PV) processes have involved PV professionals manually going through high volumes of data to identify, assess and report adverse event (AE) information. This set-up will face increasing challenges, as more and more work needs to be done in fixed amounts of time. The options for addressing the challenges can either be labor intensive or technology enabled. Technology-enabled processes have the advantage of being sustainable over time, with the added benefit of potential savings in time and costs.
More About Ben
- Cranfield School of ManagementMaster of Business Administration
- Cranfield UniversityM.Sc. Molecular Medicine
- Nottingham Trent UniversityB.Sc. Physiology & Pharmacology
- PA Consulting GroupHealthcare Management Consultant
- Astra ZenecaPatient Safety Advisor
- Janssen Pharmaceuticals (Johnson & Johnson)Pharmacovigilance Associate
- Medical Gases LtdSales Engineer (Business Development)